PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.17
Both firms show negative OCF/share. Martin Whitman would suspect an industry-wide challenge or high growth burn rates.
-0.17
Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.
No Data
No Data available this quarter, please select a different quarter.
0.78
1.25–1.5x AVXL's 0.52. Bruce Berkowitz would investigate if the competitor’s accruals hide weaker conversions.
No Data
No Data available this quarter, please select a different quarter.